| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Arthritis and Immunology, Veterans Affairs Medical Center, Northern California Institute for Research and Education, and University of California, San Francisco, CA 94121; and
Department of Anatomy, University of Oslo, Oslo, Norway
NK cells can migrate into sites of inflammatory responses or malignancies in response to chemokines. Target killing by rodent NK cells is restricted by opposing signals from inhibitory and activating Ly49 receptors. The rat NK leukemic cell line RNK16 constitutively expresses functional receptors for the inflammatory chemokine CXC chemokine ligand (CXCL)10 (CXCR3) and the homeostatic chemokine CXCL12 (CXCR4). RNK-16 cells transfected with either the activating Ly49D receptor or the inhibitory Ly49A receptor were used to examine the effects of NK receptor ligation on CXCL10- and CXCL12-mediated chemotaxis. Ligation of Ly49A, either with Abs or its MHC class I ligand H2-Dd, led to a decrease in chemotactic responses to either CXCL10 or CXCL12. In contrast, Ly49D ligation with Abs or H2-Dd led to an increase in migration toward CXCL10, but a decrease in chemotaxis toward CXCL12. Ly49-dependent effects on RNK-16 chemotaxis were not the result of surface modulation of CXCR3 or CXCR4 as demonstrated by flow cytometry. A mutation of the Src homology phosphatase-1 binding motif in Ly49A completely abrogated Ly49-dependent effects on both CXCL10 and CXCL12 chemotaxis, suggesting a role for Src homology phosphatase-1 in Ly49A/chemokine receptor cross-talk. Ly49D-transfected cells were pretreated with the Syk kinase inhibitor Piceatannol before ligation, which abrogated the previously observed changes in migration toward CXCL10 and CXCL12. Piceatannol also abrogated Ly49A-dependent inhibition of chemotaxis toward CXCL10, but not CXCL12. Collectively, these data suggest that Ly49 receptors can influence NK cell chemotaxis within sites of inflammation or tumor growth upon interaction with target cells.
This article has been cited by other articles:
|
|
 |
|
  A. THIEL, R. PRIES, S. JESKE, T. TRENKLE, and B. WOLLENBERG Effect of Head and Neck Cancer Supernatant and CpG-Oligonucleotides on Migration and IFN-{alpha} Production of Plasmacytoid Dendritic Cells Anticancer Res, August 1, 2009; 29(8): 3019 - 3025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Wuest and D. J. J. Carr Dysregulation of CXCR3 Signaling due to CXCL10 Deficiency Impairs the Antiviral Response to Herpes Simplex Virus 1 Infection J. Immunol., December 1, 2008; 181(11): 7985 - 7993. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Wagner, L. Walther-Jallow, E. Buentke, H.-G. Ljunggren, A. Achour, and B. J. Chambers Human cytomegalovirus-derived protein UL18 alters the phenotype and function of monocyte-derived dendritic cells J. Leukoc. Biol., January 1, 2008; 83(1): 56 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Rittner, D. Labuz, M. Schaefer, S. A. Mousa, S. Schulz, M. Schafer, C. Stein, and A. Brack Pain control by CXCR2 ligands through Ca2+-regulated release of opioid peptides from polymorphonuclear cells FASEB J, December 1, 2006; 20(14): 2627 - 2629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kawakami, M. Terabe, M. Kawakami, J. A. Berzofsky, and R. K. Puri Characterization of a Novel Human Tumor Antigen Interleukin-13 Receptor {alpha}2 Chain. Cancer Res., April 15, 2006; 66(8): 4434 - 4442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ito, T. Maruyama, N. Saito, S. Koganei, K. Yamamoto, and N. Matsumoto Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity J. Exp. Med., February 21, 2006; 203(2): 289 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wu, L.-P. Jin, M.-M. Yuan, Y. Zhu, M.-Y. Wang, and D.-J. Li Human First-Trimester Trophoblast Cells Recruit CD56brightCD16- NK Cells into Decidua by Way of Expressing and Secreting of CXCL12/Stromal Cell-Derived Factor 1 J. Immunol., July 1, 2005; 175(1): 61 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kamogawa-Schifter, J. Ohkawa, S. Namiki, N. Arai, K.-i. Arai, and Y. Liu Ly49Q defines 2 pDC subsets in mice Blood, April 1, 2005; 105(7): 2787 - 2792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Saudemont, N. Jouy, D. Hetuin, and B. Quesnel NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells Blood, March 15, 2005; 105(6): 2428 - 2435. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
